within Pharmacolibrary.Drugs.S_SensoryOrgans.S01E_AntiglaucomaPreparationsAndMiotics.S01EB05_Physostigmine;

model Physostigmine
  extends Pharmacolibrary.Drugs.ATC.S.S01EB05;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>S01EB05</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Physostigmine is a reversible cholinesterase inhibitor derived from the Calabar bean. It is primarily used for the treatment of glaucoma (topically), anticholinergic toxicity, and occasionally in Alzheimer's disease research. Although previously used in ophthalmology and toxicology (anticholinergic poisoning), its clinical use is limited today due to side effects, newer alternatives, and its narrow therapeutic index.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for an average healthy adult population based on review of available literature, due to limited direct recent PK model publications; values are approximate and represent typical ranges reported.</p><h4>References</h4><ol><li><p>Hartvig, P, et al., &amp; Lindström, B (1986). Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patients. <i>Acta anaesthesiologica Scandinavica</i> 30(2) 177–182. DOI:<a href=\"https://doi.org/10.1111/j.1399-6576.1986.tb02392.x\">10.1111/j.1399-6576.1986.tb02392.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3705906/\">https://pubmed.ncbi.nlm.nih.gov/3705906</a></p></li><li><p>Braden, NJ, et al., &amp; Walson, PD (1986). Tricyclic antidepressant overdose. <i>Pediatric clinics of North America</i> 33(2) 287–297. DOI:<a href=\"https://doi.org/10.1016/s0031-3955(16)35002-7\">10.1016/s0031-3955(16)35002-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3515300/\">https://pubmed.ncbi.nlm.nih.gov/3515300</a></p></li><li><p>Hurh, E, et al., &amp; Lee, MG (2000). Effects of physostigmine on the pharmacokinetics of intravenous parathion in rats. <i>Biopharmaceutics &amp; drug disposition</i> 21(8) 331–338. DOI:<a href=\"https://doi.org/10.1002/bdd.243\">10.1002/bdd.243</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11514953/\">https://pubmed.ncbi.nlm.nih.gov/11514953</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Physostigmine;
